648 results on '"Friberg, Lena E."'
Search Results
52. Research priorities towards precision antibiotic therapy to improve patient care
53. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
54. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
55. Pharmacokinetics and Immunogenicity of the First Doses of PEG-Asparaginase
56. Expert workshop summary: Advancing toward a standardized murine model to evaluate treatments for antimicrobial resistance lung infections
57. Variability of murine bacterial pneumonia models used to evaluate antimicrobial agents
58. Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects
59. Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose
60. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin‐6 and C‐reactive protein by modelling
61. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data
62. A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory
63. Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
64. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs
65. Inter occasion variability in individual optimal design
66. Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia
67. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
68. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
69. Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity.
70. Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors.
71. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
72. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
73. Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
74. Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
75. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections
76. Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
77. Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
78. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever
79. Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer
80. Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis
81. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
82. Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model
83. Continuous infusion of piperacillin‐tazobactam significantly improves target attainment in children with cancer and fever.
84. Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel
85. Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
86. CPT: Pharmacometrics & Systems Pharmacology – Inception, Maturation, and Future Vision
87. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
88. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS
89. A tool for neutrophil guided dose adaptation in chemotherapy
90. Dose response of whole-grain biomarkers: alkylresorcinols in human plasma and their metabolites in urine in relation to intake
91. Model-Informed Translation of In Vitro Effects of Short-, Prolonged- and Continuous-Infusion Meropenem against Pseudomonas aeruginosa to Clinical Settings.
92. Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms
93. Predictions of In Vivo Prolactin Levels from In Vitro K i Values of D2 Receptor Antagonists Using an Agonist–Antagonist Interaction Model
94. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer
95. Dr. Hartmut Derendorf, PhD, a world‐renowned expert in pharmacokinetics and pharmacometrics (1953–2020)
96. Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel
97. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
98. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia
99. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model
100. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.